Rebate claims validation that checks every invoice line against the contract and the formulary position the plan actually held
Every rebate invoice line checked, every dispute backed by its clause.
See one case, screen by screen ↓Checking a payer's rebate invoice claim by claim before it is paid: that each claim is eligible under the contract, billed at the rate the contract pays, and not also a 340B, State Medicaid or previously paid claim. Rebate Claims Validation adds seven agents that recalculate every invoice line and show each variance with its clause, for the rebate lead to decide.
How to choose AI solutions for life sciences →
Updated
Every quarter each PBM, health plan, Part D sponsor and managed Medicaid plan bills the manufacturer for its commercial, Part D or Medicaid rebates, with utilization files of hundreds of thousands of claims in the rebate standard or the payer's own layout. Rebate analysts check them in spreadsheets against agreements whose rates depend on amendments, schedules of opted-out groups and look-back windows — and on the formulary position the plan actually held that quarter.
That last condition is where money leaks. A plan that moved the drug to Tier 4 with step therapy on April 1 still bills the preferred-brand rate for the whole quarter, and a rate check passes it. The payer's own formulary file proves it, but it is rarely matched to each invoice line. Add 340B contract-pharmacy claims, claims also on a State Medicaid invoice and claims already paid last quarter, and a 30–45 day payment window: teams pay in full to avoid late fees, then chase.
Estimated split for one quarterly payer invoice, by hand and with the solution; the totals match the catalog's 19-day and 4.2-day figures.
Seven specialist agents read the invoice, the contract and the formulary files and recalculate every line; the rebate lead decides.
Wednesday, October 7, 2026. Harbor Union Rx sends Northwind Bio its Q2 2026 Medicare Part D rebate invoice under contract HUR-2025-022 (Amendment 1): 13 lines, 36,940 claims, $4,284,591, due November 6. Here is what happens next, screen by screen, in the working solution.
Priya's Reconciliation screen shows all ten Q2 invoices with their status: Bluepeak waiting for her signature, Crestline with 2 red lines and 6 to decide, Northgate's dispute sent, Pinecrest reconciling. Harbor Union arrived at 07:12, not reconciled. Its ledger lists six Veltrimab lines at 25%, six Corventa lines at 14% and an administrative fee at 3.4% of WAC.
“Show me the line, the clause and the formulary row, and I can decide in a minute.” — Priya Raman
The Invoice & file intake ties 36,940 claims in 2 files to the invoice total. The Contract term reader returns 7 terms in force. The Eligibility & formulary checker reads Harbor Union's Q2 formulary file and the position grid fills in month by month; the Duplicate & overlap finder and the Rate & quantity checker work through the claims. Owed under the contract: $3,629,168. Variance: $655,423.
On screen: “Reconciled 4 min after arrival” · 4 of 13 lines red · claims excluded on 6 more.
Line 3 bills 276 cartons of Veltrimab under plan benefit package S7742-004 at 25% of WAC, $302,220. The contract's § 4.2(b) pays 25% only for a whole quarter on Tier 3, without step therapy; otherwise 8%. Harbor Union's formulary file shows S7742-004 on Tier 4, non-preferred, with step therapy from 04/01/2026. Owed: $96,710. Lines 4 and 6, plans 007 and 011, turn red for the same reason.
“Position not held — lower rate owed.”
The invoice opens on its exceptions: preferred rate billed where Veltrimab was not preferred (632 claims, $470,587, 98% sure), claims filled by 340B contract pharmacies, claims already paid in Q1 and an administrative fee above 3% of WAC. The calculation is on screen — 632 cartons × 17% of the $4,380 WAC ($744.60) = $470,587 — with the three invoice lines behind it and the clause highlighted in the contract beside it.
“Recommended: dispute in full — $470,587.”
Priya disputes the formulary exception. The other three: 388 claims at the contract pharmacies of 340B covered entities, 301 also carrying Submission Clarification Code 20 ($76,320, § 6.3); 190 claims matching Q1 claims by Rx number, fill date and pharmacy ($25,482, § 8.2); and a fee charged at 3.4% against a 3% cap on $20,758,608 of WAC ($83,034, § 5.1). She applies the agents' recommendations to all three.
“The agents recommend these decisions for the 3 open exceptions. You stay the decider — each will show your name.”
The Dispute letter writer turns her decisions into one letter to Harbor Union's Manufacturer Rebate Services: items A to D with the clause, the claim count and the amount, $655,423 disputed, and a claim list attached for each item. Northwind Bio will pay the undisputed $3,629,168 by November 6. Priya sends it through the payer's portal; contract operations and GTN accounting are copied.
The letter writer includes only decided items, and a person sends the letter.
The Payment packet assembler gathers the invoice and files, the results of 10 checks, her decisions, the sent letter, the clauses cited and the calculation: $4,284,591 invoiced, $655,423 disputed, $3,629,168 to pay. It shows the true-up to GTN accounting against the $4,092,000 Q2 accrual. Priya signs: “I prepared and approve this payment.”
“Your signature, its meaning and the time are kept with the packet.”
Harbor Union's invoice is under the $25M controller threshold, so Priya's signature is the only one needed. The government pricing check records the payment as excluded from Best Price — Part D plan rebates — and Lena Ortiz is informed. The payment is scheduled in the ERP for November 5, a day before it is due, and the accrual true-up is posted.
The invoice's activity lists the validation run — 10 checks in 4 minutes, 4 exceptions — the reconciliation, each of Priya's four disputes with its amount, the drafted and sent letter, her signature with its meaning, the Best Price record and the scheduled payment, each with who and when.
On the dashboard the quarter reads: $158.7M invoiced on 10 payer invoices and 1.30M claims, $8.3M disputable found (5.2%), $1.2M recovered so far with more replies due, a 4.2-day median from receipt to decision and every invoice due so far paid on time. Formulary placement is the biggest cause at $2.5M, then 340B overlap at $1.9M.
The same invoice, seen by the five people who carry it from arrival to payment — what their quarter looked like, and what it looks like now.
Seven specialist agents read the invoice, the contract and the formulary files and recalculate every line; the rebate lead decides.
Reads payer invoices and utilization files in any layout, maps them to the rebate standard, merges main and adjustment files and ties the claims to the invoice total.
Reads each rebate agreement and every amendment and keeps the terms in force — rates, tier conditions, exclusions, fees, look-back, schedules — each linked to its clause.
Checks products, dates, plans, groups, territories and look-back, and the formulary position month by month against the tier conditions in the contract.
Finds claims billed twice across files and quarters, 340B contract-pharmacy claims and claims also on a State Medicaid invoice.
Recalculates the rebate for every claim with the rate grid and WAC history, checks administrative fees and price protection, and compares quantities with label dosing.
Turns the rebate lead's decisions into one dispute letter that cites the clause and attaches the claim list for each item.
Builds the payment packet — invoice, validation results, decisions, letter, clauses and calculation — routes it for e-signature by amount, runs the Best Price check and schedules the payment.
Decides each exception. The agents propose; a named person decides.
Ask in plain words — or tell it what to change. Answers point to the clause and the payer's rows.
Why are three Harbor Union lines red?
Three Veltrimab lines — plan benefit packages 004, 007 and 011 — were billed at the 25% preferred-brand rate. Harbor Union's own Q2 formulary file moves Veltrimab to Tier 4 with step therapy on those plans from Apr 1. The contract pays 25% only where Veltrimab holds Tier 3 for the whole quarter, otherwise 8%. Variance on the three lines: $470,587. Every other plan held Tier 3 all quarter, so those lines stand.
Why is Crestline's June exclusivity rebate disputed?
Crestline billed the 6% exclusivity rebate on all 5,440 June Veltrimab claims. The contract pays it only for months when Veltrimab is the sole preferred brand for the whole month. The June formulary file moves a competing brand, Ostravel, to Tier 2 preferred on Jun 12, so June is not an exclusive month. Disputed: $1,429,632.
Does any of this need a Best Price review?
Crestline's Veltrimab rate after disputes is 30.6% of WAC — below the 36% review threshold, so it does not need Lena Ortiz's review and does not set a new Best Price. Part D and managed Medicaid rebates are excluded from Best Price, so for Bluepeak, Northgate, Riverbend and Pinecrest the check only records the payment for government pricing.
Flag any invoice where a competing brand joined the tier mid-quarter
Done. New check: hold invoices where a competing brand joined the tier mid-quarter. It compares every monthly formulary file with the tier conditions in each contract. Across the 8 checked invoices it finds Crestline — already an exception — and nothing new elsewhere. The check is on in Settings and on the audit trail.
13 screens from the working solution, on its sample data. Pick one to see it large.
The checks the agents run, who decides and signs, and where invoices arrive are settings — each change recorded on the audit trail.
| Setting | Default | Choose from |
|---|---|---|
| Checks on every invoice line | 10 on | Each check switched on or off: product and contract dates · plan and group eligibility · formulary placement month by month · rates and fees · duplicates · 340B · Medicaid overlap · quantity · look-back · territories |
| Duplicates across files and quarters | Rx number + fill date + pharmacy, 4 quarters back | Across main, adjustment and prior-quarter files |
| 340B contract pharmacies | HRSA 340B database on the dispensing date | Plus Submission Clarification Code 20 |
| Controller signs payments above | $25M | Step up or down, $5M at a time |
| Government pricing review when the rebate is above | 36% of WAC, after disputes | Step up or down, one point at a time |
| Ask me to decide every exception above | $1,000 | Step up or down, $500 at a time; smaller exceptions follow the recommendation and are listed in the letter |
| Dispute letters are signed by | Priya Raman | Priya Raman · Sam Patel |
Every figure is labelled: a target the solution is built to, an estimate, a typical published result, or a proven one.
“demo” = seen in the working solution, on its sample Q2 2026 rebate data · “target” = the design goal, measured in the live solution · “estimated” = our estimate · “typical” = published or vendor-reported figures (a vendor-reported case of more than $5M a year of disputable rebates found; GAO-23-107056 on Part D rebates tied to preferred tier placement; Drug Channels gross-to-net analyses, 2025–2026). People, companies, payers, products and contracts named on this page are fictional — characters and sample data in the working solution.
Checking a payer's rebate invoice claim by claim before it is paid: that each claim is eligible under the contract, billed at the rate the contract pays, and not also a 340B, State Medicaid or previously paid claim. Rebate Claims Validation adds seven agents that recalculate every invoice line and show each variance with its clause, for the rebate lead to decide.
The Eligibility & formulary checker reads the payer's own formulary file and tests, plan by plan and month by month, whether the product held the position the contract pays for. A line billed at the preferred rate for a plan that moved the product to a worse tier is recalculated at the rate that position earns, and the formulary row is attached as proof.
Yes. The Duplicate & overlap finder checks each pharmacy against the HRSA 340B database on the dispensing date and reads Submission Clarification Code 20, finds claims also on a State Medicaid rebate invoice, and matches claims across files and quarters. A duplicate needs Rx number, fill date and pharmacy to match.
Yes. The Invoice & file intake reads utilization files in the NCPDP rebate standard or the payer's own layout, keeps each mapping for next time, merges main and adjustment files and ties the claims to the invoice total. It stops and asks when the totals do not tie.
No. The agents recommend; only a person disputes, part-pays or accepts. The letter includes only decided items and a person sends it, and no payment is released without the required e-signatures.
Yes. The rebate lead decides each exception and signs with the meaning of the signature, the controller co-signs above the threshold, and payments whose rebate could set a new Best Price wait for government pricing. Every step is on an immutable activity trail.
Yes. Each of the ten line checks can be switched on or off, and the controller threshold, the government pricing review threshold, the exception size that needs a person and the letter signer are settings. You can also add a check in plain words, such as holding invoices where a competing brand joined the tier mid-quarter.
The Agentic Solution Engine builds and deploys it from your requirements and documents — your rebate agreements, a sample of past payer invoices and utilization files, and the formulary files behind them — and it goes live once every quality gate has passed. We will walk you through it on your own invoices first.
Every GVD sentence linked to its source and checked against the label.
1-min demoPayer Contract ManagementEvery payer contract turned into cited terms, every deadline tracked
1-min demoPayer Coverage Policy TrackingEvery payer policy change caught within a day of posting, checked against the contract.
1-min demoWe'll run Rebate Claims Validation on a sample of your own past payer invoices and contracts.